Inimmune designs and develops novel immunotherapeutic compounds and delivery systems that target relevant pathways of the innate immune system to drive disease-modifying responses in areas of high unmet medical need. Our lead clinical programs include a TLR4 agonist, INI-2004, for seasonal allergic rhinitis and a TLR7/8 agonist, INI-4001, for cancer delivered in proprietary liposomal formulations. In addition, Inimmune develops novel vaccine adjuvants and has entered into a worldwide commercialization & distribution agreement with SPI for selected vaccine adjuvants from the Inimmune portfolio.